GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease-Reference-Cited by-同舟云学术

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease

Published:2012 Issue:4 Volume:36 Page:262
ISSN:2233-6079
Container-title:Diabetes & Metabolism Journal
language:en
Short-container-title:Diabetes Metab J

Author:

Lee Jinmi¹,Hong Seok-Woo¹,Rhee Eun-Jung²,Lee Won-Young²

Affiliation:

1. Institute of Medical Research, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

2. Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

Publisher

Korean Diabetes Association

Subject

Endocrinology, Diabetes and Metabolism

Link

https://synapse.koreamed.org/pdf/10.4093/dmj.2012.36.4.262

Reference36 articles.

1. Epidemiology of nonalcoholic fatty liver

2. From the metabolic syndrome to NAFLD or vice versa?

3. Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome

4. The Role of Incretins in Glucose Homeostasis and Diabetes Treatment

5. The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering the Gut–Liver Axis: A Comprehensive Scientific Review of Non-Alcoholic Fatty Liver Disease;Livers;2024-09-12

2. Second Generation Anti-Obesity Medications;Current Pediatrics Reports;2024-08-20

3. Assessing the therapeutic potential of long-chain isomaltooligosaccharides in diabetic and hyperlipidemic rats;Diabetology & Metabolic Syndrome;2024-07-16

4. Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence;Frontiers in Endocrinology;2024-06-24

5. Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies;World Journal of Methodology;2024-06-20